Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $8.8 million.

  • Taysha Gene Therapies' Cash from Financing Activities rose 3338.89% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $224.7 million, marking a year-over-year increase of 20865.06%. This contributed to the annual value of $76.7 million for FY2024, which is 4377.72% down from last year.
  • Taysha Gene Therapies' Cash from Financing Activities amounted to $8.8 million in Q3 2025, which was up 3338.89% from $216.3 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Cash from Financing Activities registered a high of $216.3 million during Q2 2025, and its lowest value of -$4.2 million during Q4 2023.
  • For the 4-year period, Taysha Gene Therapies' Cash from Financing Activities averaged around $32.7 million, with its median value being $377000.0 (2023).
  • Examining YoY changes over the last 5 years, Taysha Gene Therapies' Cash from Financing Activities showed a top increase of 13663786.41% in 2023 and a maximum decrease of 24579.44% in 2023.
  • Taysha Gene Therapies' Cash from Financing Activities (Quarter) stood at $41.2 million in 2022, then crashed by 110.3% to -$4.2 million in 2023, then skyrocketed by 91.6% to -$357000.0 in 2024, then skyrocketed by 2564.15% to $8.8 million in 2025.
  • Its Cash from Financing Activities was $8.8 million in Q3 2025, compared to $216.3 million in Q2 2025 and -$52000.0 in Q1 2025.